| Authors |
Cantinotti, Massimiliano ; Voges, Inga ; di Salvo, Giovanni ; Ortiz-Garrido, Almudena ; Bharucha, Tara ; Grotenhuis, Heynric ; Sabate-Rotes, Anna ; Cavigelli, Anna ; Roest, Arno ; Sendžikaitė, Skaistė ; Nolan, Oscar ; Ramcharan, Tristan ; Koubsky, Karel ; Brun, Henrik ; Petropoulos, Andreas C ; Bellsham-Revell, Hannah ; Kaneva-Nencheva, Anna ; Dinarevic, Senka Mesihovic ; Abumehdi, Mohammad Ryan ; Óskarsson, Gylfi ; Olejnik, Peter ; Doros, Gabriela ; Ojala, Tiina ; Salaets, Thomas ; Sunnegård, Jan ; Bhat, Misha ; Wacker, Julie ; Wåhlander, Håkan ; Lubaua, Inguna ; Herberg, Ulrike ; Miller, Owen ; McMahon, Colin J |
| Abstract [eng] |
Despite significant advances in knowledge and the development of guidelines, the management of hypoplastic left heart syndrome (HLHS) remains highly variable. A structured questionnaire was circulated across European Association of Paediatric & Congenital Cardiology (AEPC) affiliated centres. The aims were to evaluate standards in pre-operative assessment, types of surgery, follow-up and medical practices in children with HLHS. Thirty-one centres from 20 countries completed the survey. Delivery of babies with HLHS occurred in co-located maternity hospitals in 74% of centres; 29% were planned for spontaneous onset of labour, while 54% decided on a case-by-case basis. The preferred initial palliation was a right ventricle-pulmonary artery conduit in 55% of cases, modified Blalock-Thomas Taussig shunt (mBTTS) in 35%, and hybrid in 15% of cases. Timing for Glenn varied from 3 to 6 months of age and preoperative examination varied greatly: 65% performed cardiac catheterization and only 19% performed cardiac magnetic resonance. Stage III palliation was performed at a highly variable interval (2—6 years of age), nearly always employing an extracardiac conduit. Fenestration was routinely performed in 61% and reserved for borderline cases in 39%. All the centers adopted warfarin for the first 3–12 months after Fontan completion, and continued if a fenestration was present, while in non-fenestrated aspirin was left by most centers (e.g. 68%). However, there was a high disparity in the use of heart failure medications (e.g. in interstage I-II 35% use ACE-inhibitors, and only 26% digoxin). Follow-up practice also varied widely with only 60% employing specific protocols. Conclusion: This first multi-centre European survey from 31 centres from 20 different European countries highlighted a high practice variation in HLHS management across all the stages of Single Ventricle (Fontan) palliation. Major variations pertained to pre- and post-surgical investigations, surgical strategy for stage I and III, medical treatment regimens, and follow-up programs. (Table presented.). |
